Literature DB >> 19109744

Digoxin and digoxin-like immunoreactive factors (DLIF) modulate the release of pro-inflammatory cytokines.

K Ihenetu1, R Espinosa, R de Leon, G Planas, A Perez-Pinero, L Waldbeser.   

Abstract

OBJECTIVE: Cardiac glycosides such as digoxin and their endogenous counterpart digoxin-like immunoreactive factor (DLIF) may possess anti-inflammatory properties.
METHODS: Pro-inflammatory cytokines from human peripheral blood mononuclear cells (PBMC) were measured by ELISA using specific antibodies. Immunocytochemistry was used to localize NF-K: B.
RESULTS: Non-stimulated PBMC constitutively secreted minimum amounts of cytokines. LPS (1 mg/L) stimulation lead to steep increases in TNF-alpha, IL-6 and IL-8 concentrations with peak rises at 8 h. An 8 h delay was observed for IL-10. Increases in IL-10 were sustained for18 h period. Significant inhibition (P > 0.05) of TNF-alpha, IL-6 and IL-8 at non-toxic of digoxin concentration (< 100 nM) and DLIF (10 nM digoxin equivalent (de)) was observed whereas no such effect was seen for IL-10. Inhibition of the degradation of activated NF-K: B in the PBMC was observed with the indicated concentrations of digoxin, DLIF or Pyrrolidine dithiocarbamate (PDTC).
CONCLUSION: Digoxin and DLIF inhibit the release of proinflammatory cytokines from PBMC via NF-K: B-dependent pathway suggesting an anti-inflammatory effect.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19109744     DOI: 10.1007/s00011-008-7249-9

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  9 in total

1.  Digoxin Exhibits Neuroprotective Properties in a Rat Model of Dementia.

Authors:  Mumin Alper Erdogan; Mehmet Kirazlar; Gurkan Yigitturk; Oytun Erbas
Journal:  Neurochem Res       Date:  2022-01-21       Impact factor: 3.996

2.  Anti-inflammatory and antinociceptive activities of bufalin in rodents.

Authors:  Lili Wen; Yang Huang; Xianbiao Xie; Wan Huang; Junqiang Yin; Wenqian Lin; Qiang Jia; Weian Zeng
Journal:  Mediators Inflamm       Date:  2014-02-26       Impact factor: 4.711

3.  Prophylactic digoxin treatment reduces IL-17 production in vivo in the neonatal calf and moderates RSV-associated disease.

Authors:  Jodi L McGill; Mariana Guerra-Maupome; Sarah Schneider
Journal:  PLoS One       Date:  2019-03-25       Impact factor: 3.240

4.  Dynamic data-driven meta-analysis for prioritisation of host genes implicated in COVID-19.

Authors:  Nicholas Parkinson; Natasha Rodgers; Max Head Fourman; Bo Wang; Marie Zechner; Maaike C Swets; Jonathan E Millar; Andy Law; Clark D Russell; J Kenneth Baillie; Sara Clohisey
Journal:  Sci Rep       Date:  2020-12-18       Impact factor: 4.379

Review 5.  Covid-19 and development of heart failure: mystery and truth.

Authors:  Hope Onohuean; Hayder M Al-Kuraishy; Ali I Al-Gareeb; Safaa Qusti; Eida M Alshammari; Gaber El-Saber Batiha
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-09-04       Impact factor: 3.000

6.  Digoxin mitigates diethylnitrosamine-induced acute liver injury in mice via limiting production of inflammatory mediators.

Authors:  Mohamed E Shaker; Mohamed F Hamed; Ahmed A Shaaban
Journal:  Saudi Pharm J       Date:  2022-01-19       Impact factor: 4.562

Review 7.  Chemistry and the Potential Antiviral, Anticancer, and Anti-Inflammatory Activities of Cardiotonic Steroids Derived from Toads.

Authors:  Hesham R El-Seedi; Nermeen Yosri; Bishoy El-Aarag; Shaymaa H Mahmoud; Ahmed Zayed; Ming Du; Aamer Saeed; Syed G Musharraf; Islam M El-Garawani; Mohamed R Habib; Haroon Elrasheid Tahir; Momtaz M Hegab; Xiaobo Zou; Zhiming Guo; Thomas Efferth; Shaden A M Khalifa
Journal:  Molecules       Date:  2022-10-05       Impact factor: 4.927

8.  Antiproliferative activity of cardenolides on cell line A549: structure-activity relationship analysis.

Authors:  Salvador Enrique Meneses-Sagrero; Luisa Alondra Rascón-Valenzuela; Rogerio Sotelo-Mundo; Wagner Vilegas; Carlos Velazquez; Juan Carlos García-Ramos; Ramón Enrique Robles-Zepeda
Journal:  Mol Divers       Date:  2020-07-05       Impact factor: 2.943

9.  Epirubicin, Identified Using a Novel Luciferase Reporter Assay for Foxp3 Inhibitors, Inhibits Regulatory T Cell Activity.

Authors:  Hajime Kashima; Fumiyasu Momose; Hiroshi Umehara; Nao Miyoshi; Naohisa Ogo; Daisuke Muraoka; Hiroshi Shiku; Naozumi Harada; Akira Asai
Journal:  PLoS One       Date:  2016-06-10       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.